- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03112239
Chronic Effects Using Light-Emitting Diode Therapy (LEDT) During a Resistance Exercise Protocol for Asthmatic Patients
Chronic Effects Using Light-Emitting Diode Therapy (LEDT) During a Resistance Exercise Protocol for Moderate to Severe Asthmatic Patients: a Randomized Controlled Clinical Trial.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This research project will be prospective, analytical and of the randomized controlled clinical trial type, with blind evaluator. The sample type will be consecutive from Santa Casa de Misericórdia de São Paulo. We will study 30 adults of both sexes with moderate to severe asthma between the ages of 20 and 70, based on the sample calculation of the outcomes of this study.
Adult individuals 20 years of age or older with a diagnosis of moderate to severe asthma of both sexes, attended at the Ambulatory of Difficult Asthma Control of Santa Casa de Misericórdia de São Paulo.
Exclusion terms include subjects diagnosed as having heart disease associated with pulmonary disease, musculoskeletal pathology that may interfere with assessment or exercise, pulmonary hypertension, calcium absorption deficiency, BMI ≥ 30 or difficulty learning.
The subjects will initially be pre-evaluated by performing pulmonary function tests, peripheral muscle strength (1-RM), functional capacity tests, physical activity questionnaires and clinical control of asthma and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them associated with active LED phototherapy and another LED phototherapy placebo.
The resistance exercise protocol will be performed on the muscles: Pectoral, Large Dorsal, Brachial Biceps, Brachial Triceps, Quadriceps and Tibial Ischia. The intensity will be from 40 to 70% obtained in the 1-RM test with two to three sets of ten repetitions.
The load increase will be performed weekly (5%) according to patient tolerance. After 12 weeks all subjects were reevaluated and the last reevaluation occurred at the end of the training program. Patients will only effectively begin participating in this study after explaining the terms of the survey and by accepting written consent from the ICF.
The mean (in kg) of the resistance training protocol for lower limbs in knee extension of group 1 was 33 ± 13 kg and the mean of group 2 was 46 ± 11 kg. The sample calculation was based on the load of the quadriceps muscle, α = 0.05 and β = 95%, determining a minimum of fourteen individuals for each group. An additional 10% was added to compensate for possible losses during the protocol. Thus a minimum of fifteen individuals will be required for the study.
Linear regression models will be used to evaluate the effect of the LED on the results (absolute change and percentage) and a sensitivity analysis with the values of the results in the revaluation, adjusted by the initial value of each result. The possible correlations between the variables can be evaluated using Pearson's correlation. The level of significance adopted will be p <0.5. The analyzes were performed with SPSS 20 software.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
São Paulo, Brésil, 05415-012
- Ivan Peres Costa
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients with a medical outpatient setting less than six months; With a stable clinical picture during three months, ie without exacerbations and with optimized drug therapy.
Signed an informed consent form (TCLE) accepting participation in the research.
Exclusion Criteria:
- Diagnosis of heart disease associated with lung disease, musculoskeletal disease that may interfere with assessment or exercise, pulmonary hypertension, calcium absorption deficiency, BMI ≥ 30, or difficulty learning.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: photobiomodulation by active LEDT
The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test.
After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with active photobiomodulation by LEDT to increase peripheral muscle function post resistance training.
|
Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
Autres noms:
|
|
Comparateur placebo: photobiomodulation by Placebo LEDT
The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test.
After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with placebo LEDT photobiomodulation to increase peripheral muscle function post resistance training.
|
Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pectoral Muscular Strength by 1RM.
Délai: Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
Muscle strength will be assessed in the pectoral muscle group, using the maximal repetition (1RM) test to quantify the resistance training load (between 60 and 80%).
|
Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
|
Major Dorsal Muscular Strength by 1RM
Délai: Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
Muscle strength will be assessed in the major dorsal muscle group, using the maximal repetition (1RM) test to quantify the resistance training load (between 60 and 80%).
|
Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
|
Femoral Quadriceps Muscular Strength by 1RM
Délai: Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
Muscle strength will be assessed in the femoral quadriceps muscle group, using the maximal repetition (1RM) test to quantify the resistance training load (between 60 and 80%).
|
Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
|
Brachial Triceps Muscular Strength by 1RM
Délai: Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
Muscle strength will be assessed in the brachial triceps muscle group, using the maximal repetition (1RM) test to quantify the resistance training load (between 60 and 80%).
|
Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
|
Brachial Biceps Muscular Strength by 1RM
Délai: Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
Muscle strength will be assessed in the brachial biceps muscle group, using the maximal repetition (1RM) test to quantify the resistance training load (between 60 and 80%).
|
Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
|
Tibial Ischia Muscular Strength by 1RM
Délai: Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
Muscle strength will be assessed in the tibial ischia muscle group, using the maximal repetition (1RM) test to quantify the resistance training load (between 60 and 80%).
|
Change from Baseline Peripheral muscular Strength up to 24 weeks.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Functional Capacity by Cardiopulmonary exercise test.
Délai: Change from baseline measured by cardiopulmonary exercise test up to 24 weeks.
|
The cardiopulmonary test will be performed in an electricomagnetic braking cycle ergometer connected to a system composed of gas analysis module attached to a module flow/wave analyzer and a microcomputer BreezeCardiO2 System.
(medical Graphics Corporation - MGC, St. Paul, Mo, USA).
|
Change from baseline measured by cardiopulmonary exercise test up to 24 weeks.
|
|
Functional Capacity by Incremental Shuytle Walk Test.
Délai: Change from baseline measured by Incremental Shuttle Walk Test distance up to 24 weeks.
|
The incremental shuttle walk test was performed based on the original test description.
The patient walk from side to side in a space of 10 meters identified by two cones inserted 0.5 from each end to avoid such sudden changes in speed.
The participant was instructed to walk from cone to cone in one.
A single point that the participant must keep pace and a triple beep indicates the beginning of a new level, the height at which the participant has increased the pace.
The test comprised 12 levels, each lasting one minute.
The speed of the first level was 1.8 Km/h, with an increase of 0.17 m/s every minute until reaching a top speed of 8.53 Km/h.
The test was stopped when the participant was unable to reach the cone before the next beep.
|
Change from baseline measured by Incremental Shuttle Walk Test distance up to 24 weeks.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Luciana MM Sampaio, PhD, University of Nove de Julho
Publications et liens utiles
Publications générales
- Miranda EF, Leal-Junior EC, Marchetti PH, Dal Corso S. Acute effects of light emitting diodes therapy (LEDT) in muscle function during isometric exercise in patients with chronic obstructive pulmonary disease: preliminary results of a randomized controlled trial. Lasers Med Sci. 2014 Jan;29(1):359-65. doi: 10.1007/s10103-013-1359-5. Epub 2013 Jun 7.
- Dourado VZ, Tanni SE, Antunes LC, Paiva SA, Campana AO, Renno AC, Godoy I. Effect of three exercise programs on patients with chronic obstructive pulmonary disease. Braz J Med Biol Res. 2009 Mar;42(3):263-71. doi: 10.1590/s0100-879x2009000300007.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ERAMG-LED-PL-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Entraînement en résistance
-
Second Affiliated Hospital of Wenzhou Medical UniversityRésiliéImmersion Virtual Reality Training, AVC, membre supérieur, essai contrôlé randomiséChine
Essais cliniques sur Light-Emitting Diode Therapy (LEDT)
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiréCarcinome épidermoïde récurrent de la lèvre et de la cavité buccale | Carcinome épidermoïde récurrent de l'oropharynx | Carcinome verruqueux récurrent de la cavité buccale | Carcinome épidermoïde de stade I de la lèvre et de la cavité buccale | Carcinome épidermoïde de stade I de l'oropharynx et d'autres conditionsÉtats-Unis
-
Roswell Park Cancer InstituteComplétéCancer de la thyroïde récurrent | Cancer folliculaire de la thyroïde de stade II | Cancer papillaire de la thyroïde de stade II | Cancer épidermoïde du cou métastatique récurrent avec primitif occulte | Cancer récurrent des glandes salivaires | Carcinome épidermoïde récurrent de l'hypopharynx et d'autres conditionsÉtats-Unis
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)ComplétéCancer du poumon non à petites cellules récurrent | Cancer du poumon non à petites cellules de stade 0 | Cancer du poumon à cellules squameuses | Adénocarcinome du poumon | Cancer du poumon à grandes cellulesÉtats-Unis
-
VA Office of Research and DevelopmentPortland VA Medical CenterRecrutementTrouble de stress post-traumatique | Lésion cérébrale traumatique légèreÉtats-Unis
-
National Cancer Institute (NCI)RésiliéCancer de la prostate récurrent | Cancer de la prostate de stade I | Adénocarcinome de la Prostate | Cancer de la prostate de stade IIA | Cancer de la prostate de stade IIBÉtats-Unis
-
Seth DisnerComplété
-
National Cancer Institute (NCI)Résilié
-
Roswell Park Cancer InstituteComplétéCancer du poumon non à petites cellules de stade IIIA | Cancer du poumon non à petites cellules de stade IIIB | Carcinome pulmonaire non à petites cellules récurrent | Carcinome pulmonaire non à petites cellules de stade IIA | Carcinome pulmonaire non à petites cellules de stade IIBÉtats-Unis
-
Roswell Park Cancer InstituteNational Institutes of Health (NIH); Biolitec Pharma Ltd.RetiréCancer de la langue | Carcinome épidermoïde récurrent de la lèvre et de la cavité buccale | Carcinome épidermoïde récurrent de l'oropharynx | Carcinome verruqueux récurrent de la cavité buccale | Carcinome épidermoïde de stade I de la lèvre et de la cavité buccale | Carcinome épidermoïde... et d'autres conditions
-
Ohio State University Comprehensive Cancer CenterRetiréCancer du poumon non à petites cellules de stade IIIB | Cancer du poumon non à petites cellules de stade IV | Mésothéliome malin de stade III | Mésothéliome malin de stade IV